Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions.
Phelan-McDermid syndrome, also called 22q13 deletion syndrome, is a genetic disorder caused by deletion of part of chromosome 22 or a defect in a gene called SHANK3. Symptoms can include intellectual disability, motor skill deficits, delayed or absent speech, autism spectrum disorder, and minor dysmorphic features.
The Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) drugs in development market research report provide comprehensive information on the therapeutics under development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aelis Farma SASAlisbio LLC
AMO Pharma Ltd
Coronis NeuroSciences Ltd
Encue LLC
Jaguar Gene Therapy LLC
Neuren Pharmaceuticals Ltd
Oryzon Genomics SA
PYC Therapeutics Ltd
Quiver Bioscience Inc
Table of Contents
Table
Figures
Frequently asked questions